PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijclbiowww.springer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
Indian J Clin Biochem. 2006 March; 21(1): 142–146.
PMCID: PMC3453763

Effect of increasing duration of diabetes mellitus type 2 on glycated hemoglobin and insulin sensitivity

Abstract

Non-insulin dependent diabetes mellitus (NIDDM) is the most rapidly growing chronic metabolic disorder in the world. With advancement in the age and duration of diabetes there is a gradual tendency for the level of blood sugar to rise along with a subsequent increase in the HbA1c as well as in the fasting insulin level. Whether this is an aging process or increased frequency of diabetes is still controversial. The correlation between glucose and insulin sensitivity is consistent with the idea that the degree of chronic hyperglycemia is a cause of excessive insulin resistance in type 2 diabetes, i.e. the insulin resistance which characterizes type 2 diabetes but not nondiabetic subjects matched for age, gender, family history and duration of diabetes. The study comprised a total of 76 subjects out of which 30 were normal, non-diabetic persons and the rest 46 were diabetics with different duration of time in years, after being diagnosed diabetic. Data was analyzed after dividing the subjects into four groups—Group 1 comprised of one year old diabetics, Group 2 was made up of those, who had diabetes, for the past 2–5 years, Group 3 included patients who were diabetic since more than 5 years and Group 4 included non-diabetics as the normal control group. The results obtained indicated that the HbA1c levels showed a significant increase with the duration of diabetes as well as the insulin level showed a significant correlation after adjustment for age, sex and duration of diabetes.

Full Text

The Full Text of this article is available as a PDF (61K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. (1995); 44: 968–983.
2. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes, (UKPDS 35) prospective observational study. BMJ. 2002;321:405–412. doi: 10.1136/bmj.321.7258.405. [PMC free article] [PubMed] [Cross Ref]
3. Burm H.F., Haney D.N., Grabbay K.H., et al. Further identification of the nature and the linkage of the carbohydrates in hemoglobin. Alc Biochem. Biophys. Res. Comm. 1975;67:103–109. doi: 10.1016/0006-291X(75)90289-2. [Cross Ref]
4. Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin. Chim. Acta. 1968;22:296–298. doi: 10.1016/0009-8981(68)90372-0. [PubMed] [Cross Ref]
5. Trivelli L.A., Ranney H.M., Lai H-T. Hemoglobin components in patients with diabetes mellitus. N. Engl. J. Med. 1971;284:353–357. [PubMed]
6. Arnetz B.B., Kallner A., Theorell T. The influence of aging on HbA1c. J. Gerontol. 1982;37:648–650. [PubMed]
7. Kilpatrick E.S., Dominiczak M.H., Small M. The effects of aging on glycation and the interpretation of glycemic control in type 2 diabetes. Q.J. Med. 1996;89:307–312.
8. Kabadi U.M. Glycosylation of proteins. Lack of influence on aging. Diabetes Care. 1998;11:421–432.
9. Defronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM: A balanced overview. Diabetes Care. 1992;15(3):318–368. doi: 10.2337/diacare.15.3.318. [PubMed] [Cross Ref]
10. Mykkanen L., Zaccaro D.J., Hales C.N., Festa A., Haffner S.M. The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed type 2 diabetes: The Insulin Resistance Atherosclerosis Study. Diabetologia. 1999;42(9):1060–1066. doi: 10.1007/s001250051271. [PubMed] [Cross Ref]
11. The expert committee on the diagnosis and classification of diabetes mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;10:1183–1197.
12. David M., Nathan M.D. Initial management of glycemia in type 2 diabetes mellitus. NEJM. 2002;347(17):1342–1349. doi: 10.1056/NEJMcp021106. [PubMed] [Cross Ref]
13. Rao G.M., Morghom L.O., Abukhris A.A., Mansori S.S., Alphgih F.A., Ragale L.Y. HbA1c and blood glucose levels in Libyan diabetic patients. Trop. Geogr. Med. 1986;38(4):391–397. [PubMed]
14. Shera A.S., Jawad F., Maqsood A., Jamal S., Azfar M., Ahmed U. Prevalence of chronic complications and associated factors in type 2 diabetes. J. Pak. Med. Assoc. 2004;54(2):54–59. [PubMed]
15. Sampson M.J., Hughes D.A., Carrier M.J., Davies I.R. Status of HbA1c during acute hyperglycemia in type 2 diabetes. Diabetes care. 2002;25:537–541. doi: 10.2337/diacare.25.3.537. [PubMed] [Cross Ref]
16. Rosetti L., Giaccari A., Defronzo R. Glucose toxicity. Diabetes care. 1990;13:610–630. doi: 10.2337/diacare.13.6.610. [PubMed] [Cross Ref]
17. Yki-Jarvinen H. Glucose toxicity. Endocr Rev. 1992;13:415–431. doi: 10.1210/er.13.3.415. [PubMed] [Cross Ref]
18. Mandarino L., Baker B., Rizza R., Genest J., Gerich J. Infusion of insulin repairs human adipocyte, glucose metabolism in vitro without decreasing adipocyte insulin receptor binding. Diabetologia. 1984;27:358–363. doi: 10.1007/BF00304850. [PubMed] [Cross Ref]
19. Mathews D., Hosker J., Naylor B. Insulin resistance and beta-cell functioning from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883. [PubMed] [Cross Ref]
20. Reaven G. Pathophysiology of insulin resistance in human disease. Physiol. Rev. 1995;75:473–486. [PubMed]
21. Meneilly G.S., Tessier D. Diabetes in the elderly. Diabet. Med. 1995;12:949–960. doi: 10.1111/j.1464-5491.1995.tb00405.x. [PubMed] [Cross Ref]
22. Evans J.L., Goldfine I.D. Glucose Status in Postmenopausal women. Endocr. Rev. 2002;23:599–622. doi: 10.1210/er.2001-0039. [PubMed] [Cross Ref]
23. Mayumi O., Seiji N., Yoko I., Eiko Y., et al. Effects of Post-menopausal Hormone Replacement Therapy on HbA1c levels. Diabetes care. 2003;26:1088–1092. doi: 10.2337/diacare.26.4.1088. [PubMed] [Cross Ref]
24. Clark C.M., Vinicor F. Introduction: Risks of benefits of intensive management in NIDDM. The Fifth Regenstrief. Conference. Ann. Intern. Med. 1996;124:81–85. [PubMed]
25. Colwell J.A. The feasibility of intensive insulin management in NIDDM: Implications of the Veterans Affairs Cooperative Study on Glycemic Control and complications in NIDDM. Ann. Intern. Med. 1996;124:131–135. [PubMed]
26. Kitabchi A.E., Bryer Ash M. NIDDM: New aspects of management. Hosp. Pract. 1997;32:135–164.
27. Gloria-Botthini F., Antonacci E., Bottini N., Ogana A., Borgiani P., Santis G., Lucarini N. Rh blood groups and diabetic disorders: Is there an effect on glycosylated hemoglobin level? Hum. Biol. 2000;72(2):287–294. [PubMed]

Articles from Indian Journal of Clinical Biochemistry are provided here courtesy of Springer